COMMUNIQUÉS West-GlobeNewswire

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10/01/2025 - 23:00

Craig Swandal, experienced medical device manufacturing executive, joins leadership team ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and [...]

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

10/01/2025 - 23:00

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

10/01/2025 - 22:30

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]

Codexis Announces New Employment Inducement Grants

10/01/2025 - 22:05

REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of [...]

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10/01/2025 - 22:01

WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]

Yaqrit appoints new CEO Troels Jordansen to implement late clinical development and commercial strategy

10/01/2025 - 21:08

Experienced private and public listed CEO Successful fund raising and business development track record New CEO available during JPM25 in San Francisco LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late-stage [...]

Virbac : Declaration of the number of shares and voti

10/01/2025 - 19:01

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

Virbac : Déclaration d'actions et de droits de vote 12/2024

10/01/2025 - 19:01

DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]

Ensuring the continuity of IBA's Entrepreneurial Anchoring

10/01/2025 - 17:47

Confirmation of the sale of IBA shares to Management Anchorage Louvain-la-Neuve, Belgium, 10 January 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, confirms that the sale by [...]

Pérennisation de l’ancrage entrepreneurial d’IBA

10/01/2025 - 17:47

Confirmation de la cession d’actions IBA à Management Anchorage Louvain-la-Neuve, Belgique, le 10 janvier 2025 - IBA (Ion Beam Applications SA), le leader mondial de la technologie des accélérateurs de particules, [...]

Adam Ferrari Health Science Scholarship Application Window Closes

10/01/2025 - 16:30

DENVER, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The application period for the 2024 Adam Ferrari Health Science Scholarship , sponsored by The Ferrari Foundation, has officially closed. This $20,000 scholarship program, [...]

Microbot Medical Closes $8.6 Million Registered Direct Offering

10/01/2025 - 16:25

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the [...]

Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

10/01/2025 - 16:21

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, [...]

PETVIVO HOLDING, INC. ANNOUNCES PARTNERSHIP ENGAGEMENTS WITH VEDCO, INC. AND CLIPPER DISTRIBUTING, LLC

10/01/2025 - 15:45

MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) ("PetVivo"), a pioneering biomedical technology company focused on adapting human biotech, medical device and other [...]

Cytosurge annonce une transition stratégique de sa direction

10/01/2025 - 15:32

Simon Egli est nommé directeur général tandis que Pascal Behr, cofondateur, devient membre du conseil d’administration ZURICH, Suisse, 10 janv. 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, leader de la manipulation [...]

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

10/01/2025 - 15:26

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase [...]

Les détecteurs Focus HD et le système de radiologie mobile DRX-Rise de Carestream reçoivent l’autorisation de marquage CE par l’Union européenne

10/01/2025 - 15:11

ROCHESTER, New York, 10 janv. 2025 (GLOBE NEWSWIRE) -- Carestream Health a annoncé ce jour avoir reçu l’autorisation de marquage CE de l’Union européenne pour ses détecteurs Focus HD et son système de radiologie mobile [...]

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder

10/01/2025 - 15:02

Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related Depression MUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering [...]

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

10/01/2025 - 15:00

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and [...]